VALHALLA
THERAPEUTICS
Biotechnology for better health
Valhalla Therapeutics is a privately-held biopharmaceutical development company that is paving the way for early commercialization of groundbreaking therapeutic technology! Founded in 2019 and based in Berwyn, PA, we're on a thrilling journey to revolutionize healthcare!
Our pipeline represents our philosophy of identifying the best unique approaches to fill the underserved therapeutic needs of disease states. As new mechanisms of action can offer a larger impact beyond incremental advances in treatment over current therapies, we strive to develop novel classes of agents possessing breakthrough potential to help patients, reduce healthcare costs and deliver maximal ROI for our investors rather than developing “me-too” follow-on drugs.
Halting The Progression Of Type 2 Diabetes:
is our most advanced program currently in the pre-IND stage of development. Based on the breakthrough research conducted by Dr. Salim Merali and Dr. Wayne Childers at Temple University, VTX-31 is a designer compound with a novel mechanism of action that directly inhibits the lipotoxicity induced by highly elevated fatty acid levels causing insulin-resistance of Type 2 diabetes and ultimately leading to its complications. Studies in multiple animal models of genetic Type 2 diabetes and diet-induced obesity/Type 2 diabetes have demonstrated reversal of insulin-resistance by increasing glucose uptake into various tissues and providing long-term glucose control. We are actively pursuing private and non-dilutive funding for this program as it is IND-capable.
No agent has been developed that directly addresses the underlying cause of T2D
Restoring Vascular Blood Flow To Tissues In Type 1 and 2 Diabetes